Designated in the manufacturer’s lot-traceability system as CZ-XL-VAPI, Cangzhu Xianglian Powder Veterinary Grade API is a standardized botanical powder for further pharmaceutical conversion into tablets, injections after extraction and aseptic filtration, capsules, powders, granules, premixes, and solutions. The suffix code is batch-specific: -D designates dry-dosage-form grades with tighter particle size control, while -L designates liquid-extraction feedstock with additional endotoxin reporting. Representative release boundaries include moisture ≤ 5.0%, total ash ≤ 7.0%, acid-insoluble ash ≤ 2.0%, and d90 between 105 μm and 180 μm for the dry-dosage-form grade. Packaging is supplied in sealed low-density polyethylene liners inside fiber drums of 5 kg, 10 kg, or 25 kg net weight. The powder is controlled for marker-compound content by high-performance liquid chromatography; because published harmonized monographs for this specific botanical combination remain limited, the exact lot-specific berberine hydrochloride or equivalent index compound concentration is stated on the certificate of analysis. The material is intended for licensed veterinary pharmaceutical manufacturing and is not a finished premix for direct farm administration.

Unlike a finished veterinary drug product, this API is not released with a target animal safety or efficacy claim. Its fitness for use is demonstrated by downstream formulation studies and the final drug product dossier. Manufacturers using CZ-XL-VAPI in sterile injections must validate depyrogenation and sterile filtration processes under current good manufacturing practice principles. The powder itself is not sterilized by gamma irradiation because irradiation can alter alkaloid marker content and produce oxidative degradation products; if sterile API is required, the manufacturer must use a validated extraction and aseptic processing route.

What Limits Direct Use of Botanical Fine Powders in Sterile Injection Lines?

Direct use of crude CZ-XL-VAPI powder in injectable vehicles is not permitted, because undissolved plant cell debris and insoluble botanical fragments increase subvisible particulate counts and may exceed USP <788> limits for particles ≥ 10 μm and ≥ 25 μm. Injectable manufacture requires a clarified or purified extract. Bacterial endotoxin control is also binding for parenteral feeds: endotoxin acceptance for an injectable-grade extract is typically established at < 0.5 EU/mg by Ph. Eur. 2.6.14 or USP <85> after depyrogenation. Aqueous extracts of this botanical matrix may contain water-soluble polysaccharides and weakly basic alkaloid salts; upward pH adjustment above pH 8.0 can reduce alkaloid solubility and produce visible precipitation. Sterile filtration should therefore be conducted only after clarification through 0.45 μm and then membrane filtration through 0.22 μm polyethersulfone or polyvinylidene fluoride membrane in an ISO 5 filling zone. Heat sterilization of the final filled solution may be inappropriate if the marker alkaloids degrade under autoclave conditions; published stability data for coptisine-type alkaloids indicate time-dependent loss at 121°C in aqueous media, so aseptic filtration is the preferred terminal processing route.

Aqueous extraction of CZ-XL-VAPI-L for injectable work is performed in jacketed reactors with temperature control at 80°C ± 5°C and continuous agitation. The extract is concentrated under vacuum at ≤ 60°C to avoid thermal degradation of alkaloid markers. Particulate matter is monitored by light obscuration particle counter calibrated per USP <788>. The final injectable solution should meet target-species osmolality; adjustment with sodium chloride or dextrose is made after filtration. Incompatibility with polyvinyl chloride infusion bags has not been fully excluded; the manufacturer should evaluate sorption of alkaloid markers to PVC and polyolefin materials during holding studies.

For tablet compression on rotary equipment, CZ-XL-VAPI-D is first passed through a conical mill fitted with a 0.8 mm or 1.0 mm screen. Blending with microcrystalline cellulose and croscarmellose sodium in a twin-shell blender is continued until the final blend Hausner ratio is ≤ 1.35 and Carr index is ≤ 25. Published tableting studies of high-fiber botanical powders report capping and lamination when granule moisture falls below 2.5%, because residual elastic recovery in the dried botanical matrix is not absorbed by ductile excipients. On a 16-station rotary press at 50–65 kN main compression force, magnesium stearate is restricted to 0.5% w/w and 5 min blending time; longer lubricant exposure can reduce tablet tensile strength and slow dissolution. Capsule filling on an automatic dosator or tamping-pin machine requires d90 ≤ 150 μm and moisture 3.0–5.0% to maintain fill weight within ± 3% and avoid rat-holing.

Particle Size Distribution and Blend Uniformity in Premix and Granule Operations

In premix and granule operations, the powder is diluted with attapulgite, corncob meal, lactose, or sodium sulfate carriers. Segregation is observed when the particle size span (d90-d10)/d50 exceeds 2.0; production-scale twin-shell blender trials with free-flowing carriers therefore restrict the span to 1.4–2.0 and maintain an API-carrier particle size ratio below 1:6. If the final premix is intended for pelleted feed, wet granulation in a high-shear granulator at impeller speed 300 rpm and chopper speed 1500 rpm is used with purified water or 2.0% w/w hydroxypropyl methylcellulose binder solution. Fluid-bed drying to an outlet temperature of 55–60°C preserves the powder’s alkaloid markers while reducing granule moisture to ≤ 4.0%. Granules intended for sachet filling are dry-screened through 1.0 mm and 0.5 mm sieves to maintain a granule fraction between 0.25 mm and 1.0 mm.

In aqueous solution preparation, CZ-XL-VAPI-L is extracted in purified water at 80–90°C for 1–2 h, then cooled and clarified through a plate-and-frame filter press or disk-stack centrifuge. The resulting extract is adjusted to pH 4.0–4.5 with citric acid, passed through 0.45 μm prefiltration, and then sterile-filtered if the finished solution is intended for injection. For oral solutions and drinking-water concentrates, the extract is preserved with potassium sorbate at 0.1–0.2% w/v and filled into high-density polyethylene containers. Solutions made from this powder should not be mixed with strong alkaline electrolytes because precipitation of alkaloid markers occurs above pH 8.0. Exposure to iron(III) ions should also be avoided because phenolic components in the botanical matrix can form dark-colored complexes that reduce filter throughput and discolor the solution.

Granulation of CZ-XL-VAPI with water in a high-shear mixer increases the activity of residual enzymes and can accelerate hydrolysis of polysaccharides if the wet mass is held at 25–30°C for more than 30 min. Process data from botanical granulation lines show that wet mass hold times above 45 min can produce batch-to-batch variation in alkaloid recovery of more than 5%. The granulation is therefore transferred to the fluid-bed dryer within 30 min and dried at inlet air temperature of 60–70°C. Product temperature should not exceed 50°C for more than 1 h because marker alkaloids may degrade under prolonged moist heat. Terminal drying of granules to ≤ 4.0% moisture is checked by loss on drying at 105°C.

When a Botanical Multi-Component API Replaces a Single-Marker Extract

The principal difference between CZ-XL-VAPI and a single-marker product such as purified berberine hydrochloride is that the botanical API retains a wider set of alkaloid, polysaccharide, and lignan-derived constituents. This multi-component profile can change dissolution behavior and final solution viscosity in ways that single-marker crystalline powders do not. In tablet formulations, the botanical powder contributes higher hygroscopicity and greater tablet friability unless moisture is controlled at 3.0–5.0% and microcrystalline cellulose is included at 20–30% w/w. By contrast, purified berberine hydrochloride formulates more predictably as a crystalline salt but lacks the auxiliary botanical constituents that may be required in a specific veterinary formula. Commodity pulverized herb powder is less controlled: particle size is usually unreported, microbial load is variable, and marker content is not standardized across harvest lots. CZ-XL-VAPI differs from both by applying pharmaceutical-grade milling, blend uniformity testing, heavy metal and microbial limits, and marker reporting to a botanical multi-component input. However, retention of auxiliary constituents also creates a broader impurity and allergen profile; extractable polysaccharides may increase solution viscosity and may require enzymatic hydrolysis in some liquid lines.

For granules and premixes, batch-to-batch variance in bulk density can exceed ± 10% if the milling screen is changed from 0.8 mm to 1.2 mm without adjusting carrier ratio. Process control therefore fixes the screen aperture and requires incoming excipient bulk density within 0.30–0.60 g/mL. When the powder is dry-mixed into premixes at 10–20% w/w API loading, blend uniformity testing by HPLC on 10 sampling points should show relative standard deviation ≤ 5.0%. If the mixture is intended for direct solution reconstitution, the final powder should be protected from relative humidity above 60%, because hygroscopic uptake above 6.0% moisture promotes clumping and reduces flow through rotary valves. Compatibility with acidifiers and organic acids in drinking-water formulations is acceptable within the usual final solution pH range of 3.5–5.0; combinations with strong alkalis, cationic metal salts, and oxidizing agents are not recommended without site-specific stability data.